Torrent Pharmaceuticals (NSE:TORNTPHARM) Total Receivables: ₹33,408 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:TORNTPHARM Torrent Pharmaceuticals Ltd NSE:TORNTPHARM
86 GF Score
Price ₹4,987.60
GF Value ₹4,385.23
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Torrent Pharmaceuticals Total Receivables?

Torrent Pharmaceuticals NSE:TORNTPHARM -0.60% 86 Total Receivables is ₹33,408 Mil as of Mar. 2026. GuruFocus rates NSE:TORNTPHARM with a GF Score™ of 86/100 and a GF Value™ of ₹4,385.23 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Torrent Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was ₹33,408 Mil.

Torrent Pharmaceuticals Total Receivables Related Terms

Torrent Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Torrent Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Torrent Pharmaceuticals Total Receivables Chart

Torrent Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,296.60 21,257.30 20,912.30 21,258.80 33,408.00

Torrent Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21,258.80 0.00 21,900.00 0.00 33,408.00
NSE:TORNTPHARM
86GF Score
Torrent Pharmaceuticals Ltd NSE:TORNTPHARM
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Torrent Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹33,408 Mil mean?
Torrent Pharmaceuticals (NSE:TORNTPHARM) has a Total Receivables of ₹33,408 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Torrent Pharmaceuticals and its competitors.
Is Torrent Pharmaceuticals' Total Receivables too high?
Torrent Pharmaceuticals' current Total Receivables is ₹33,408 Mil. Overall, Torrent Pharmaceuticals has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Torrent Pharmaceuticals' Total Receivables compare to ZTS and UTHR?
Torrent Pharmaceuticals' Total Receivables of ₹33,408 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Torrent Pharmaceuticals and its competitors. Torrent Pharmaceuticals's current Total Receivables is ₹33,408 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Torrent Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Torrent Pharmaceuticals (NSE:TORNTPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹4,385.23, compared to a current price of ₹4,987.60 — trading 13.7% above its estimated fair value. The current Total Receivables is ₹33,408 Mil. Torrent Pharmaceuticals' overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Torrent Pharmaceuticals (NSE:TORNTPHARM), the current Total Receivables is ₹33,408 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Torrent Pharmaceuticals stock appears to be overvalued. The current stock price of ₹4,987.60 is trading 13.7% above its estimated GF Value™ of ₹4,385.23. GuruFocus considers Torrent Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for NSE:TORNTPHARM:

  • Total Receivables: ₹33,408 Mil
  • GF Value™: ₹4,385.23 vs. price of ₹4,987.60 (13.7% above fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the NSE:TORNTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Torrent Pharmaceuticals Business Description

Other Exchanges 500420:India
Address Off Ashram Road, Torrent House, Ahmedabad, GJ, IND, 380009
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
86GF Score

Get the complete analysis for NSE:TORNTPHARM

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,987.60
Price
₹4,385.23
GF Value